Our findings demonstrate that inhibiting TGF‐β signaling enhances the size of subcutaneous white adipocytes and improves hyperglycemia and dyslipidemia in aP2‐SREBP‐1c mice. Here, SREBF1 is linked to metabolic syndrome.